95 related articles for article (PubMed ID: 9295983)
1. [Severe local cutaneous necrosis during treatment with interferon-alpha and ribavirin for chronic viral hepatitis C].
de Ledinghen V; Brudieux E; Beylot-Barry M; Belleannee G; Doutre MS; Couzigou P
Gastroenterol Clin Biol; 1997; 21(6-7):523-4. PubMed ID: 9295983
[No Abstract] [Full Text] [Related]
2. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
Jensen SL; Holmes R
J Drugs Dermatol; 2003 Oct; 2(5):554-6. PubMed ID: 14558405
[TBL] [Abstract][Full Text] [Related]
3. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Sood A; Midha V; Bansal M; Goyal A; Sharma N
Indian J Gastroenterol; 2006; 25(6):324. PubMed ID: 17264447
[No Abstract] [Full Text] [Related]
4. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin.
Misery L
J Interferon Cytokine Res; 2002 Aug; 22(8):881-2. PubMed ID: 12396727
[TBL] [Abstract][Full Text] [Related]
5. [Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C].
Yaghi C; Baz P; Koussa S; Daniel F; Haddad F; Sayegh R
Gastroenterol Clin Biol; 2005 May; 29(5):616-7. PubMed ID: 15980766
[No Abstract] [Full Text] [Related]
6. [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
García-Toro M; Vilella Martorell A; Carral Martínez M; Jimeno Beltrán T; Román Ruiz del Moral Y; Pradas Guerrero C; Gili Planas M; Roca Bennasar M
Gastroenterol Hepatol; 2011 Apr; 34(4):307-8. PubMed ID: 21376422
[No Abstract] [Full Text] [Related]
7. Psychotic mania induced by the withdrawal of pegylated interferon and ribavirin treatment.
Ganeshalingam Y; Suleman S; Francis M
Br J Hosp Med (Lond); 2009 Apr; 70(4):233. PubMed ID: 19357605
[No Abstract] [Full Text] [Related]
8. Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin.
Werchniak AE; Cheng SX; Dhar AD; Klaus SN
Clin Exp Dermatol; 2004 Sep; 29(5):547-8. PubMed ID: 15347347
[No Abstract] [Full Text] [Related]
9. New combination treatment for hepatitis C is more beneficial than standard therapy, study says.
Levenson D
Rep Med Guidel Outcomes Res; 2002 Oct; 13(20):5-6. PubMed ID: 12599388
[No Abstract] [Full Text] [Related]
10. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
[No Abstract] [Full Text] [Related]
11. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Yachimski P; Chung RT
AIDS Read; 2004 Oct; 14(10):568-9. PubMed ID: 15510393
[No Abstract] [Full Text] [Related]
13. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.
Hoffman RG; Cohen MA; Alfonso CA; Weiss JJ; Jones S; Keller M; Condemarín JR; Chiu NM; Jacobson JM
Psychosomatics; 2003; 44(5):417-20. PubMed ID: 12954918
[No Abstract] [Full Text] [Related]
14. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
[TBL] [Abstract][Full Text] [Related]
15. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lafeuillade A; Hittinger G; Chadapaud S
Lancet; 2001 Jan; 357(9252):280-1. PubMed ID: 11214134
[TBL] [Abstract][Full Text] [Related]
16. Side effects. Bone problems may occur with hepatitis treatment.
TreatmentUpdate; 2000 Sep; 12(6):7-8. PubMed ID: 12132465
[No Abstract] [Full Text] [Related]
17. Face skin hyperpigmentation during pegylated interferon and ribavirin therapy.
Yaşar B; Yaşar Ş; Güneş P
Turk J Gastroenterol; 2015 Mar; 26(2):189-90. PubMed ID: 25835121
[No Abstract] [Full Text] [Related]
18. Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
Bektas M; Bektas H; Gören D; Altan M; Cetinkaya H
Digestion; 2007; 75(4):208-9. PubMed ID: 17934275
[No Abstract] [Full Text] [Related]
19. Psychiatric aspects of hepatitis C treatment.
Vrbanac DB; Buljan D; Sindik I; Gelo J; Sakoman LN
Acta Clin Croat; 2013 Sep; 52(3):346-52. PubMed ID: 24558767
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
